Target lowered to 5$ from 15$ at HC Wainwright Oncolytics price target lowered to $5 from $15 at H.C. Wainwright H.C. Wainwright lowered the firm's price target on Oncolytics to $5 from $15 and keeps a Buy rating on the shares. The analyst says pelareorep demonstrated encouraging efficacy in anal cancer, while the company's clinical development path in pancreatic cancer shifts. The target drop reflects an increase in estimated expenses related to pela's clinical development and a potential launch in 2027, the analyst tells investors in a research note.
Got this summary from Thefly.com
You can get more info by clicking on the link if you create a free account and sign in.
I find it quite useful at times for getting info on my investments. Cheers!!!!!!!!!!!!!!!!!!!!!